News

Morphic Therapeutic announced that it has entered into a research and development collaboration with Janssen Biotech, Inc. (Janssen) to discover and develop novel integrin therapeutics…
Read More...

QIAGEN N.V. announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V., to develop innovative bioinformatics and assay solutions to accelerate research targeting the…
Read More...

A new way to plan radiotherapy could help shape treatment away from sensitive organs near tumours to reduce side-effects, a new study shows. The technique has been developed by…
Read More...

BiomX Ltd. announced the closing of a $32 million series B equity financing. The financing was led by existing investors OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda…
Read More...

NanoSphere Health Sciences Inc. announced the signing of a definitive Licensing Agreement with Oregon cannabis company Cascade Pure, LLC. The Agreement gives Cascade Pure the exclusive…
Read More...

Knight Therapeutics Inc. announced it has entered into a secured loan and exclusive License Agreement with privately-held Triumvira Immunologics. The US$5 million secured loan has a…
Read More...

Indivior PLC announced that its U.S. affiliate, Indivior Inc., has launched an authorized generic version of SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) in the U.S. The…
Read More...

Torque, a clinical-stage immuno-oncology company developing first-in-class Deep Primed T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced that…
Read More...

Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in…
Read More...

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for upadacitinib for the treatment of adult…
Read More...

Pfizer Inc. and Eli Lilly and Company announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). In…
Read More...

NEW ORLEANS & Ochsner Health System, Louisiana’s largest non-profit academic healthcare system, and Pfizer Inc have entered into a multi-year strategic alliance to develop…
Read More...

Aucta Pharmaceuticals announced that it has entered into an agreement with Oakrum Pharma, LLC (Oakrum) to develop and manufacture four prescription generic pharmaceutical products that…
Read More...

Exicure, Inc. and Dermelix Biotherapeutics announced a license and development agreement to advance SNA therapeutics in rare genetic skin diseases. Under the terms of agreement,…
Read More...

STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, and BioLingus, a Swiss biotech company, announce they have formed an exclusive technology and marketing…
Read More...

Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin…
Read More...

Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the…
Read More...

Eli Lilly and Company announced the successful completion of its acquisition of Loxo Oncology. The acquisition broadens the scope of Lilly's oncology portfolio into precision medicines…
Read More...

Innovent Biologics announced the signing of a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences) to evaluate the safety and tolerability of…
Read More...